• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Covetrus Inc.

    10/13/22 11:19:58 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care
    Get the next $CVET alert in real time by email
    S-8 POS 1 d411849ds8pos.htm S-8 POS S-8 POS

    Registration Statement No. 333-229557

    As filed with the Securities and Exchange Commission on October 13, 2022

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 1 to

    Form S-8

    Registration Statement

    No. 333-229557

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Covetrus, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   83-1448706

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    7 Custom House Street

    Portland, Maine 04101

      04101
    (Address of Principal Executive Offices)   (Zip Code)

    Covetrus, Inc. 2019 Omnibus Incentive Compensation Plan

    Covetrus, Inc. Employee Stock Purchase Plan

    Direct Vet Marketing, Inc. 2010 Stock Incentive Plan, as amended

    (Full titles of the plans)

    Margaret B. Pritchard

    General Counsel & Secretary

    Covetrus, Inc.

    7 Custom House Street

    Portland, ME 04101

    (Name and Address of Agent for Service)

    (888) 280-2221

    (Telephone Number, Including Area Code, of Agent for Service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
    Emerging growth company   ☐     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    On October 13, 2022, Covetrus, Inc., a Delaware corporation (“Covetrus” or the “Company”), completed the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 24, 2022 (the “Merger Agreement”), by and among Covetrus, Corgi Bidco, Inc., a Delaware corporation (“Parent”), and Corgi Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”). Pursuant to the Merger Agreement, Merger Sub merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent.

    This Post-Effective Amendment (the “Post-Effective Amendment”) relates to the Registration Statement on Form S-8 (No. 333-229557) (the “Registration Statement”) filed by the Company with the Securities and Exchange Commission (the “Commission”) on February 7, 2019, relating to the registration of 17,658,228 shares of the Company’s common stock, par value $0.01 per share, under the Covetrus, Inc. 2019 Omnibus Incentive Compensation Plan, the Covetrus, Inc. Employee Stock Purchase Plan and the Direct Vet Marketing, Inc. 2010 Stock Incentive Plan. The Company is filing this Post-Effective Amendment to withdraw and remove from registration any and all securities of the Company that had been registered under the Registration Statement but remain unsold or not yet issued.

    As a result of the Merger, the Company has terminated all offerings of securities pursuant to the Registration Statement. By filing this Post-Effective Amendment, the Company hereby terminates the effectiveness of the Registration Statement and, in accordance with the undertakings made by the Company in the Registration Statement, removes from registration any and all securities registered under the Registration Statement that remain unsold or not yet issued as of the date hereof.

     

    2


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Maine, on October 13, 2022.

     

    COVETRUS, INC.
    By:  

    /s/ Margaret B. Pritchard

      Name: Margaret B. Pritchard
      Title: General Counsel & Secretary

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933, as amended.

     

    3

    Get the next $CVET alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVET

    DatePrice TargetRatingAnalyst
    6/13/2022$22.00Buy → Hold
    Stifel
    5/23/2022Outperform → Mkt Perform
    Raymond James
    11/18/2021$19.00Equal-Weight
    Morgan Stanley
    11/5/2021$37.00 → $27.00Outperform
    Raymond James
    8/9/2021$46.00 → $38.00Overweight
    Barclays
    8/6/2021$38.00 → $37.00Outperform
    Raymond James
    8/5/2021$29.00Neutral
    Credit Suisse
    7/12/2021$30.00Neutral → Buy
    Guggenheim
    More analyst ratings

    $CVET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares

    4 - COVETRUS, INC. (0001752836) (Issuer)

    10/13/22 11:44:56 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    SEC Form 4: Helton Sandra L returned 38,095 shares to the company, closing all direct ownership in the company

    4 - COVETRUS, INC. (0001752836) (Issuer)

    10/13/22 11:08:02 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    SEC Form 4: Laskawy Philip A returned 15,064 shares to the company, closing all direct ownership in the company

    4 - COVETRUS, INC. (0001752836) (Issuer)

    10/13/22 11:07:42 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    $CVET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Covetrus downgraded by Stifel with a new price target

    Stifel downgraded Covetrus from Buy to Hold and set a new price target of $22.00

    6/13/22 7:15:59 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    Covetrus downgraded by Raymond James

    Raymond James downgraded Covetrus from Outperform to Mkt Perform

    5/23/22 7:13:08 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    Morgan Stanley initiated coverage on Covetrus with a new price target

    Morgan Stanley initiated coverage of Covetrus with a rating of Equal-Weight and set a new price target of $19.00

    11/18/21 8:28:56 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    $CVET
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

    Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

    8/8/24 9:00:00 AM ET
    $SEMR
    $CVET
    Computer Software: Prepackaged Software
    Technology
    Other Pharmaceuticals
    Health Care

    Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

    NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

    10/13/22 5:50:00 PM ET
    $CVET
    $MLKN
    $SPGI
    Other Pharmaceuticals
    Health Care
    Office Equipment/Supplies/Services
    Consumer Discretionary

    Covetrus Names Michelle Bonfilio as Chief People Officer

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

    9/26/22 4:00:00 PM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    $CVET
    SEC Filings

    View All

    SEC Form 15-12G filed by Covetrus Inc.

    15-12G - COVETRUS, INC. (0001752836) (Filer)

    10/24/22 11:12:59 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    SEC Form S-8 POS filed by Covetrus Inc.

    S-8 POS - COVETRUS, INC. (0001752836) (Filer)

    10/13/22 11:19:58 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)

    SC 13E3/A - COVETRUS, INC. (0001752836) (Subject)

    10/13/22 11:17:50 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    $CVET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

    SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

    10/13/22 11:50:30 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

    SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

    5/25/22 12:15:30 PM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

    SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

    5/20/22 8:00:28 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    $CVET
    Financials

    Live finance-specific insights

    View All

    Covetrus Announces Financial Results for Second Quarter of 2022

    Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

    8/4/22 8:00:00 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

    4/29/22 8:00:00 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

    Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

    2/24/22 4:01:00 PM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    $CVET
    Leadership Updates

    Live Leadership Updates

    View All

    Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

    Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

    8/8/24 9:00:00 AM ET
    $SEMR
    $CVET
    Computer Software: Prepackaged Software
    Technology
    Other Pharmaceuticals
    Health Care

    Covetrus Names Michelle Bonfilio as Chief People Officer

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

    9/26/22 4:00:00 PM ET
    $CVET
    Other Pharmaceuticals
    Health Care

    Covetrus Names Margie B. Pritchard General Counsel

    Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

    8/26/22 8:00:00 AM ET
    $CVET
    Other Pharmaceuticals
    Health Care